14th – 16th July 2022

University Hospital Bern

9TH I-DSD SYMPOSIUM



Bern, Switzerland





Welcome Remarks

Dear Friends and Colleagues,

On behalf of the I-DSD steering committee, it is with great pleasure that we welcome you to Bern for the 9th International Symposium on the Differences & Disorders of Sex Development from the 14th-16th July 2022.

These meetings have been very successful in attracting a rapidly expanding multidisciplinary group of experts, eager to discuss the latest advances in the field and have laid the foundation for fruitful international collaborations. The meeting will consist of invited speakers and original communications and there will be a workshop for investigators who are interested in performing clinical research in DSD and for those who would like to use the I-DSD Registry. In addition to the prizes for the best original communications and posters, there will be additional prizes in several categories representing the multiple disciplines that are involved in this field.

The meeting will be held at the Inselspital University Children's Hospital Bern. This meeting was originally scheduled to be held in Bern in 2021 and had been replaced by a webinar. However, we are glad that this year we can go back to Switzerland, a country that has led the way in our understanding of many endocrine conditions including those that lead to DSD.

We would like to acknowledge the generous support of several sponsors including; Swiss National Science Foundation, Swiss Society of Paediatric Endocrinology and Diabetology, Spruce Biosciences, Diurnal, Novo Nordisk, EffRx, Pfizer, Merck, Neurocrine Biosciences, Karger, Sandoz, University Hospital Bern, University of Bern, University of Glasgow, Office for Rare Conditions, European Society for Paediatric Endocrinology (ESPE), Endo-ERN, Pediatric Endocrine Society, Australasian Paediatric Endocrine Group

As organizing committee we look forward to an enriching meeting, together with you. A symposium meant to be a stimulating scientific and friendly environment, where initiatives can be initiated to further increase knowledge and understanding and translation to care.

We would particularly like to thank Jillian Bryce, Karyn Cooper and Martin McMillan in Glasgow and Marianne Nussbaum in Bern for their administrative and organsiational support.

Christa Flück, Local Host & Incoming Chair of I-DSD Steering Committee Anna Nordenström, Chair of I-DSD Steering Committee Faisal Ahmed, I-DSD Project Lead

General Information

Meeting Venue:	Auditorium Ettore Rossi, Inselspital University Children's Hospital Bern, Freiburgstrasse 15, 3010 Bern
Workshop Venue:	Auditorium Ettore Rossi, Inselspital University Children's Hospital Bern, Freiburgstrasse 15, 3010 Bern
Internet:	Password available upon registration
Badges:	Name badge upon registration. Permits access to Symposium Sessions and catering facilities. (Does not permit access to DSD training workshop - separate registration required)
Meals:	Lunch and coffee breaks included in registration fee.
Social Evening	Dinner on Friday evening, 15 th July 2022. Entry by pre-ordered ticket only - supplied in registration pack. Restaurant Sole, U2 at University Children's Hospital, Bern
Accreditation:	<u>UEMS-EACCME</u> for 11 hours CME. Compatible with USA and Canadian CME schemes. CME Certificates will be provided upon completion of an on-line feedback survey.
Feedback Survey:	https://link.webropol.com/s/idsd2022feedback
Local Organisers:	Christa Flück, Claudia Böttcher, Malou Nussbaum, Marianne Nussbaum, Grit Sommer, Bern
Programme Organising Committee:	Anna Nordenström, I-DSD SC Chair, Stockholm Christa Flück, Bern Faisal Ahmed, Jillian Bryce, Karyn Cooper, Martin Mcmillan, DSD management, Glasgow Violeta Iotova, Varna Sabine Hannema, Amsterdam Angela Lucas-Herald, Glasgow
Additional Support:	Special thanks to the DSD Bern team for additional ground support
Supported by:	Sponsors listed on the back of programme

I-DSD Symposium

Thursday 14th - Saturday 16th July 2022 All Sessions in the Ettore Rossi Auditorium

SYMPOSIUM DAY 1 (THURSDAY, JULY 14TH 2022)

Registration & Coffee from 11:30 (Foyer)	
13:00	Opening
Session 1 – Setting the Scene (13:00-13:35) Chair: Anna Nordenström, Stockholm, Sweden	
13:05 - 13:20	Welcome - Christa Flück, Bern, Switzerland Patients' experiences in Switzerland Patient support & advocacy – Arlene Smyth, Turner Syndrome International
	ternational Collaboration (13:40-14:15) Ahmed, Glasgow, UK
13:45 - 13:50 13:50 - 13:55 13:55 - 14:00	Endo-ERN – Olaf Hiort, Lübeck Germany ESPE DSD working group – Tülay Güran, Istanbul, Turkey APEG DSD Working Group – Michele O'Connell, Melbourne, Australia PES DSD Working Group – Courtney Finlayson, Chicago, USA I-DSD/I-CAH – Christa Flück, Bern, Switzerland

14:05 – 14:15 Discussion

Oral Communications 1 (OC1) (14:20-15:30) Chairs: Rade Vukovic, Belgrade, Serbia, Angela Lucas-Herald, Glasgow, UK

14:20 - 14:30	Current management of acute adrenal insufficiency related adverse
	effects in children with congenital adrenal hyperplasia – results of an
	international survey of specialist – Salma Ali, Glasgow, UK
14:30 - 14:40	Identification of small regions of overlap from copy number variable
	regions reveals candidate genes and novel chromosome loci for
	hypospadias – Ina Amarillo, St Louis, USA
14:40 - 14:50	The international SF1 next project: Description of a cohort of 107
	individuals with SF-1/NR5A1 variants – Chrysanthi Kouri, Bern,
	Switzerland

SYMPOSIUM DAY 1 (THURSDAY, JULY 14TH 2022)

14:50 - 15:00	Pathway to Care among People with Disorders of Sex Development:
	Cohort Profile – David E Sandberg, Ann Arbor, USA
15:00 - 15:10	Designing a best-worst scaling survey for defining successful outcomes
	and trade-offs in DSD care – Erica Weidler, Phoenix, USA
15:10 - 15:20	A novel POR variant recurrently found in Argentine patients results in a
	wide spectrum of undervirilised phenotypes in 46,XY patients – Jimena
	Lopez Dacal, Buenos Aires, Argentina
15:20 - 15:30	Timing of reconstructive surgery for individuals with differences of sex
	development (DSD): Stakeholder views on successful outcomes –
	Kathleen van Leeuwen, Phoenix, USA

Coffee Break 15:30 – 16:00

Session 3 – Reaching A Genetic Diagnosis In The Era Of NGS (16:00-17:30)
Chair: Olaf Hiort, Luebeck, Germany

The clinical approach – Ruth McGowan, Glasgow, UK
Advances in insilico analysis – Katie Ayers, Melbourne, Australia
Functional analysis – Anu Bashamboo, Paris, France
Discussion
-

Free Evening

SYMPOSIUM DAY 2 (FRIDAY, JULY 15TH 2022)

Session 4 –Adrenal & Gonadal Development (08:15-09:45) Chair: Amit Pandey, Bern, Switzerland	
08:15 - 08:40 08:40 - 09:05	Mouse models for DSD – Serge Nef, Geneva, Switzerland Novel therapeutic models for adrenal disorders – Leo Guasti, London, UK
09:05 - 09:30 09:30 - 09:45	Novel models of the gonads – Anna Lauber-Biason, Fribourg, Switzerland Discussion
Oral communications 2 (OC2) (09:50-11:00) Chairs: Meilan Rutter, Cincinnati, USA, Grit Sommer, Bern, Switzerland	
09:50 - 10:00	Caregiver Perceptions of Stigma Associated with their Child's Difference of Sex Development – Kristina I. Suorsa-Johnson, Salt Lake City, USA
10:00 - 10:10	-
10:10 - 10:20	"I believe God doesn't make mistakes, and I am wonderfully made in His image": The intersection of religion/faith and clinical care in Differences of Sex Development – Meilan Rutter, Cincinnati, USA
10:20 - 10:30	Experiences and needs of variation in sex characteristics peer support members in the prenatal setting – Michele O'Connell, Melbourne, Australia
10:30 - 10:40	46,XY Partial gonadal dysgenesis; diagnosis and long-term outcome at puberty – Rieko Tadokoro Cuccaro, Cambridge, UK
	Genital skin wound healing is associated with the extent of external virilisation in boys with hypospadias – Angela Lucas-Herald, Glasgow, UK
10:50 - 11:00	Psychological impact on parents of children born with atypical genitalia in India – Tanvi Bindal, New Delhi, India

Coffee Break 11:00 – 11:30

Session 5 – Hypospadias – a disorder of sex development or not (11:30 – 13:00) Chair: Margarett Shnorhavorian, Seattle, USA

Acquired or genetic – Jorma Toppari, Turku, Finland
The views of an endocrinologist – Sabine Hannema, Amsterdam,
Netherlands
The views of a psychologist -Norma Ruppen, Zurich, Switzerland
The views of a surgeon – Emilie Johnson, Chicago, USA
Round table

Lunch 13:00 - 14:00

Session 6 – Debate (14:00 – 15:15) 'This house believes that clinical psychology care should be provided proactively in every case of atypical genitalia'

14:00 - 14:05	Introduction and poll – Christa Flueck, Bern, Switzerland
14:05 - 14:25	For – Vickie Pasterski, Cambridge, UK
14:25 - 14:45	Against – David Sandberg, Ann Arbor, USA
14:45 - 15:15	Discussion & poll

Coffee and Posters **15:15** – **15:30**

		1 (0 10)	
15:30 – 17:30 G	uided poster ro	unds (Ground floor)	

19:30 - Social Evening

SYMPOSIUM DAY 3 (SATURDAY JULY 16TH 2022)

Session 7 – Endocrine aspects at transition & beyond (09:00 – 10:45) Chair: Carla Bizzari, Rome, Italy	
09:00 - 09:25	Importance of transition for long term care – Philippe Touraine, Paris,
	France
09:25 - 09:50	Management of hypogonadotropic hypogonadism – Julia Rohayem,
	Munster, Germany
09:50 - 10:15	Assisted conception in Klinefelters -Claus Gravholt, Aarhus
10:15 - 10:40	Long-term psychosocial outcome – Baudewijntje Kreukels, Amsterdam,
	Netherlands
10:40 - 10.50	Discussion

Coffee Break 10:50 - 11:15

Session 8 – Future Directions (11:15 – 13:15) Chair: Hedi Claahsen, Nijmegen, Netherlands

11:15 - 11:40	Incorporating DSD concepts in the undergraduate curriculum – Ina
	Amarillo, St Louis, USA
11:40 - 12:05	The role of patient organisations in influencing care and research –
	Johan de Graaf, Netherlands
12:05 - 12:30	Incorporating the ethical dimension into clinical practice – Jürg Streuli,
	Zurich, Switzerland
12:30 - 12:55	Benchmarking of care in DSD & CAH – Justin Davies, Southampton, UK
12:55 - 13:15	Discussion

13:15 - Close (Faisal Ahmed)

Optional Small Group Networking Breakout With Packed Lunch 13:15-14:30

I-DSD Training Workshop *Thursday July 14th 2022* (09:00 -12:30) Ettore Rossi Auditorium, Course Rooms 1, 2 & 3

The I-DSD/I-CAH/I- TS registries	Bioinformatic analysis	Communication with a new parent or patient	Interpretation of endocrine tests
Angela Lucas- Herald/Salma Ali Glasgow, UK	Amit Pandey Bern, Switzerland	Katie Traino Oklahoma City, USA	Tülay Güran Istanbul, Turkey

The Training Workshop is an additional event. The full programme is available to registered workshop participants



The 9th International DSD Symposium, Bern, Switzerland, 14/07/2022-16/07/2022 has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME[®]) with 11 European CME credits (ECMEC[®]s). Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.

Feedback survey

Please complete the evaluation feedback survey to obtain your CME (CPD) attendance certificate



https://link.webropol.com/s/idsd2022feedback

Abstracts:

Available in upcoming on-line Special Issue of Sexual Development, Karger

Poster Presentations

PO 1 A digital network for professionals providing psychosocial care in DSD

<u>Arianne Dessens</u>· Erasmus Medical Center Rotterdam, Sophia Children's Hospital, Rotterdam, The Netherlands.

PO 2 Sexual self-concept in women with DSD

<u>Arianne Dessens</u>· Erasmus Medical Center Rotterdam, Sophia Children's Hospital, Rotterdam, The Netherlands.

PO 3 Cognitive executive functioning in relationship to karyotype in children with monosomy x

<u>Arianne Dessens</u>· Erasmus Medical Center Rotterdam, Sophia Children's Hospital, Rotterdam, The Netherlands.

PO 4 Information Sharing in DSD: The Creation of a Caregiver-Support Tool

<u>Kristina Suorsa-Johnson</u>, Department of Pediatrics, University of Utah Spencer Fox Eccles School of Medicine, Salt Lake City, UT, USA

PO 5 Defining Successful Outcomes and Trade-offs in Differences of Sex Development: Parlaying Stakeholder Valuations into Educational Resources for Healthcare Providers

<u>Kristina Suorsa-Johnson</u>, Department of Pediatrics, University of Utah Spencer Fox Eccles School of Medicine, Salt Lake City, UT, USA

PO 6 Optimizing delivery of care for individuals with differences of sex development (DSD): Defining successful outcomes and trade-offs

<u>Meilan Rutter</u>, Division of Endocrinology, Cincinnati Children's Hospital Medical Center, University of Cincinnati, Cincinnati, OH, USA

PO 7 Defining success in the delivery of fertility-related care for patients with differences of sex development

<u>Meilan Rutter</u>, Division of Endocrinology, Cincinnati Children's Hospital Medical Center, University of Cincinnati, Cincinnati, OH, USA

PO 8 Frequency analysis of ten years' experience in a multidisciplinary clinic of pediatric patients with differences of sexual development in Mexico City

Mariana Zamora-Ángeles, Genetics Department, Hospital Infantil de México, México City, Mexico

PO 9 Exploring Prenatal Testing for Difference of Sex Development from a Genetic Healthcare Providers' Perspective

<u>Michele O'Connell</u>, University of Melbourne, Royal Children's Hospital, Murdoch Children's Research Institute, Melbourne, Australia

PO 10 Prenatal ultrasound and genetic evaluation of atypical genitalia in possible Disorders/ Differences of Sex Development - Counseling aspects and outcome

<u>Yolande van Bever</u>, DSD Expert Center, Erasmus University Medical Center, Rotterdam, The Netherlands

PO 11 Testosterone or DHT treatment during first year of life had no effect on behavior in boys with 46,XY DSD

<u>Carl Lundeberg</u>, Endocrinology, Karolinska University Hospital and Karolinska Institutet, Stockholm, Sweden

PO 12 Understanding and implementing the new German legislation on "protecting children with variation of sex development" – psychological and sociological perspectives *Katinka Schweizer,* Department of Psychology, MSH Medical School Hamburg, Germany

PO 13 Digital photography in the evaluation and management of female patients with congenital adrenal hyperplasia: a standardized protocol for quality improvement *Julie Cheng*, Division of Urology, Seattle Children's Hospital, Seattle, USA

PO 14 Integration of Child Life services in the delivery of multi-disciplinary Differences in Sexual Development (DSD) and Congenital Adrenal Hyperplasia (CAH) care

Julie Cheng, Division of Urology, Seattle Children's Hospital, Seattle, USA

PO 15 Cross-Cultural Disparities in Psychosocial Research of Individuals with Classical Congenital Adrenal Hyperplasia: A Scoping Review *Katherine Traino*, Oklahoma State University, USA

PO 16 A single-institution retrospective chromosome microarray analysis of copy number variations in non-coding regions of genes detected in patients with differences of sex development

Armando Sanchez-Conde, School of Arts and Sciences, Washington University, St Louis, MO, USA

PO 17 Clinical and genetic analysis of six patients with atypical testicular development <u>*Daniela Mateo-Madrigal*</u>, Department of Genetics, Hospital Infantil de México, Mexico City, Mexico

PO 18 Two novel mutations in MCM8 gene in a 46, XX female with short stature, primary ovarian insufficiency and kidney dystopia

<u>Ekaterina Kvaratskhelia</u>, Department of Endocrinology, Tbilisi state Medical University, Ilia State University, Tbilsi, Georgia

PO 19 Whole exome sequencing advances a genetic diagnosis in patients with differences of sex development and corroborates the role of RXFP2 in autosomal recessive bilateral cryptorchidism and infertility

Hannes Syryn, Center for Medical Genetics Ghent, Ghent University Hospital, Ghent, Belgium

PO 20 Can noncoding NR5A1 gene variants explain phenotypes of Disorders of Sex Development? <u>Helena Fabbri-Scallet,</u> Center for Molecular Biology and Genetic Engineering - CBMEG, State University of Campinas, São Paulo, Brazil

PO 21 Three novel NR5A1 variants in individuals with 46,XY DSD fail to activate a SOX9 enhancer

<u>Gabby Atlas</u>, Murdoch Children's Research Institute, University of Melbourne, Royal Children's Hospital, Victoria, Australia, Parkville VIC 3052, Australia

PO 22 Genetic diagnosis of DSD : NRC Experience

Inas Mazen, Human Cytogenetics Department., National Research Centre, Cairo, Egypt Not present

PO 23 Increased Expression of ZFPM2 Bypasses SRY to Drive 46,XX Testicular Development: A New Mechanism of 46,XX DSD

Louise C Pyle, Children's Hospital of Philadelphia, Philadelphia, PA, USA

PO 24 Homozygosity for a novel INHA mutation in two male siblings with hypospadias, primary hypogonadism, and high normal testicular volume

<u>Tulay Guran</u>, Department of Pediatric Endocrinology and Diabetes, Marmara University, School of Medicine, Istanbul, Turkey

PO 25 Contribution of Next Generation Sequencing to the molecular diagnosis of patients with Disorders/differences of Sex Development

<u>Veronica Calonga Solis</u>, Medical Systems Biology Division, Lübeck Institute of Experimental Dermatology and Institute for Cardiogenetics, University of Lübeck, Lübeck, Germany.

PO 26 Overview of the Genetics in Disorders of Sex Development at an Academic Hospital in Pretoria, South Africa: What is going on?

<u>Maria Karsas</u>, Department of Paediatric Endocrinology, University of Pretoria, ²Steve Biko Academic Hospital, Gezina, South Africa,

PO 27 Comprehensive Cytogenetic Study of a Large Cohort of Egyptian Referral Patients with Disorders of Sex Development (DSD)

Mona Mekkawy, Human Cytogenetics Department., National Research Centre, Cairo, Egypt

PO 28 Spectrum of SF-1/NR5A1 gene variants in the large international SF1next cohort

<u>Idoia Martinez de Lapiscina</u>, Pediatric Endocrinology, Diabetology and Metabolism, Department of Pediatrics, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland

PO 29 Said's Procedure, (Modified Fenton's Procedure) as a unique solution for Vaginal Stenosis, as a longterm complication of Vaginoplasty

Bshaer Albaihani, International Medical Center, Jeddah, KSA

PO 30 Pediatric Adnexal Torsion, Primary and Secondary, Clinical presentation and Single incision Laparoscopic Surgery (SILS) Management

Bshaer Albaihani, International Medical Center, Jeddah, KSA

PO 31 International variations in Vaginal Lengthening Treatments among Individuals with Mayer-Rokitansky-Küster-Hauser (MRKH) Syndrome

<u>Christine Pennesi</u>, University of Michigan, Michigan Medicine, Department of Obstetrics and Gynecology, Ann Arbor, MI, USA

PO 32 Vaginal Lengthening Treatment Experiences among Individuals with Mayer-Rokitansky-Küster-Hauser (MRKH) Syndrome

<u>Christine Pennesi</u>, University of Michigan, Michigan Medicine, Department of Obstetrics and Gynecology, Ann Arbor, MI, USA

PO 33 Decision-making regarding orchiectomy in patients with 17-beta-hydroxysteroid dehydrogenase type 3 deficiency: Clinical considerations

<u>Christine Pennesi</u>, University of Michigan, Michigan Medicine, Department of Obstetrics and Gynecology, Ann Arbor, MI, USA

PO 34 The Multidisciplinary team approach importance in the parents' decision-making process

<u>Eduardo Correa Costa</u>, Pediatric Surgery Service, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil

PO 35 Feminizing genitoplasty in 46,XX Congenital Adrenal Hyperplasia patients: a tertiary centre experience

<u>Eduardo Correa Costa</u>, Pediatric Surgery Service, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil

PO 36 It was supposed to be a boy with hypospadias and unilateral undescended testicle, now what?

<u>Eduardo Correa Costa</u>, Pediatric Surgery Service, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil

PO 37 Predictors of surgical outcomes in boys with hypospadias

<u>Kathryn Scougall</u>, Developmental Endocrinology Research Group, School of Medicine, Dentistry & Nursing, University of Glasgow, Glasgow, UK

PO 38 Attitudes toward fertility-related care and education of youth and young adults with differences of sex development: informing future care models

<u>Emilie K Johnson</u>, Division of Urology, Department of Surgery, Lurie Children's Hospital of Chicago, ²Department of Urology, Northwestern Feinberg School of Medicine, Chicago, Illinois, USA

PO 39 The DSD Translational Research Network: A platform for discovery and improved clinical care

<u>Emmanuèle Délot</u>, Center for Genetic Medicine Research, Children's National Research Institute and Department of Genomics and Precision Medicine, George Washington University, Washington, D.C., USA

PO 40 Psychosocial Adjustment in Youth with 17-beta Hydroxysteroid Dehydrogenase 3 Deficiency: A Case Series

<u>Jaclyn L. Papadakis</u>, Pritzker Department of Psychiatry and Behavioral Health, Ann & Robert H Lurie Children's Hospital of Chicago, Chicago, Illinois, USA

PO 41 Change in newborn registration legislation for individuals with Disorders/Differences of Sex Development

<u>Guilherme Guaragna-Filho</u>, Department of Pediatrics, Universidade Federal do Rio Grande do Sul, DSD Team (PADS), Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil

PO 42 Denys-Drash syndrome with Focal Segmental Glomerulosclerosis and novel WT1 mutation: a case report

<u>Guilherme Guaragna-Filho</u>, Department of Pediatrics, Universidade Federal do Rio Grande do Sul, DSD Team (PADS), Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil

PO 43 Spectrum of DSD disorders at Haukeland University Hospital, Norway from 1998-2018 <u>Helge Raeder</u>, Department of Clinical Science, University of Bergen, Haukeland University Hospital, Bergen, Norway

PO 44 Endocrine and Genetic Evaluation of XY Boys Investigated For A Disorder Of Sex Development

<u>Malika Alimussina</u>, Developmental Endocrinology Research Group, University of Glasgow, Royal Hospital for Children, Glasgow, UK

PO 45 Immunohistochemical characterization of Leydig cells in gonadal tissues from adolescent and adult patients with complete androgen insensitivity syndrome

<u>Mostafa Al-Sharkawi</u>, Section of Pediatric Endocrinology and Diabetology, Center of Brain, Behaviour and Metabolism, University of Lübeck, Lübeck, Germany

PO 46 Comprehensive Multidisciplinary Digital Pixel Phenotyping of Patients with Hypospadias *Nicolas Fernandez*, Division of Urology, Seattle Children's Hospital, Seattle, WA, USA

PO 47 Central Precocious Puberty in Congenital Adrenal Hyperplasia. Data from a Single Center <u>Renata Markosyan</u>, Yerevan State Medical University, Yerevan, Armenia

PO 48 Development and validation of a short version of the Quality of Life DSD questionnaire (QoL-DSD) for parents of young children with disorders/differences of sex development Salma Ali, Developmental Endocrinology Research Group, Royal Hospital for Children, Office for Rare Conditions, University of Glasgow, Glasgow, UK

PO 49 Sexually dimorphic visual perception of sex characteristics: an eye-tracking study *Zofia Kolesinska,* Department of Pediatric Endocrinology and Rheumatology, Poznan University of Medical Sciences, Karol Jonscher's Children Hospital, Poznan, Poland

PO 50 DSD clinical coordinator role: Impact on clinical care

<u>Chloe Hanna</u>^{1,2,3}, Melbourne Medical School, University of Melbourne, Murdoch Children's Research Institute, Royal Children's Hospital, Melbourne, Australia

PO 51 Case series of 16 patients with 17β -hydroxysteroid dehydrogenase type 3 deficiency at five children's hospitals in the United States

Courtney Finlayson, Pediatric Endocrinology, Lurie Children's Hospital, Chicago, IL, USA

PO 52 Leukocyte telomere length in children with congenital adrenal hyperplasia

<u>Ozair Abawi,</u> Division of Endocrinology, Department of Pediatrics, Erasmus MC-Sophia, University Medical Center Rotterdam, Rotterdam, The Netherlands

Sponsors

The Organising Committee would like to thank all of the supporters of the I-DSD Symposium

